Cervical Cancer Drugs Market Trends in 2020, Industry Share, Size Analysis, Growth Insights, Opportunities, Business Forecast by 2026 | Exclusive Reportage by CMI
SEATTLE, April 01, 2021, (PHARMIWEB) — Cervical cancer is a type of cancer that develops in women’s cervix and mainly affects sexually active women aged between 30 and 45. Cervical cancer doesn’t show any symptoms at the initial phase. Cervical cancer can be diagnosed by using a Pap test (Papanicolaou test), which is a screening test that can identify the changes taking place in the cervix before the development of cancer. The most common type of cervical cancer is squamous cell cancer and adenocarcinoma.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1746
The rising number of drug approval done by the U.S. Food and Drug Administration (FDA) for the treatment of cervical cancer is projected to drive the growth of the cervical cancer drug market over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, the U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.
Furthermore, rising funding for cancer research, improving insurance coverage, and growth in the number of new targeted cancer drugs are expected to support the revenue growth of the cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research, which includes cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, the U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/39xumnY
Rising incidence of cervical cancer among the global population, growth in incidence of HIV in women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected to drive the growth of the cervical cancer drugs market. Moreover, the American Cancer Society, in March 2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data findings, around 3,200 new cervical cancer cases were registered in the UK annually from 2013 to 2015.
Moreover, according to the same source, in 2015, cervical cancer accounted for around 2% of all cancer cases in females in the UK. A joint study conducted on cervical cancer by the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and National Institute of Cancer Prevention and Research (NICPR), published in January 2018, reported that India alone has one fourth of the global burden of cervical cancer, which accounts for 17% of all cancer deaths in women aged between 30 and 69 years in India. Moreover, according to the same source, it is estimated that around 1 in 53 Indian women are expected to be diagnosed with cervical cancer during their lifetime.
Geographically, the cervical cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a dominant position in the cervical cancer drugs market, and this can be attributed to increasing incidences of cervical cancer and growing research & development programs by various healthcare regulatory organizations in these region. For instance, according to the American Cancer Society’s (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed and around 4,170 women are expected to die from cervical cancer. For instance, in 2013, Cervical Cancer-Free Coalition (CCFC) announced a collaborative research projects with funds ranging from US$ 5,000-US $10,000 each, which are focused on cervical cancer treatment in the U.S.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1746
Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance their market share and retain their competence in the market. For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. This study is conducted to develop a treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.
By Cancer Type:
- Squamous Cell Cancer
By Drug Type:
- By Prevention
- Gardasil 9
- Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
- Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine
- Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine
- By Treatment
- Avastin (Bevacizumab)
- Blenoxane (Bleomycin)
By Distribution Channels:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1746
Table of Content
Global Cervical Cancer Drugs Market Research Report
Section 1: Global Cervical Cancer Drugs Industry Overview
Section 2: Global Economic Impact on Cervical Cancer Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Cervical Cancer Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Cervical Cancer Drugs Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire